PreludeDx™ to Present Data in DCIS and Stage I, II Early Breast Cancer at the 2024 Miami Breast Cancer Conference

/PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced that...

Related Keywords

Cleveland Clinic ,Florida ,United States ,Miami Beach ,Michigan ,Miami ,Franka Vicini ,Troy Bremer ,Andrew Wade ,Chirags Shah ,Dan Forche ,Cory Dunn ,Prelude Corporation Preludedx ,Linkedin ,National Cancer Institute ,Taussig Cancer Institute ,University Of California San Francisco ,Department Of Radiation Oncology ,Facebook ,Instagram ,Prelude Corporation ,Breast Cancer Conference ,Novel Biosignature ,Early Stage Invasive Breast Cancer ,Assess Recurrence Risk ,Patients Treated ,Chief Scientific Officer ,Radiation Therapy Recommendation ,Treatment Modality ,Ductal Carcinoma ,Situ Using ,Gene Biosignature ,Breast Radiation Oncology ,Radiation Oncology ,Clinicopathologic Factors Alone ,Predicting Radiation Benefit ,Breast Conserving Surgery ,Gene Biosignature Based ,Ipsilateral Breast Recurrence ,Radiation Oncologist ,Michigan Healthcare Professionals ,California San Francisco ,Decision Score ,Know Your Risk ,Fjord Ventures ,Preludedx ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Biotechnology ,Conference Call Announcements ,